-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
EOM PHARMACEUTICAL HOLDINGS, INC. ANNOUNCES NAME CHANGE FROM IMMUNOCELLULAR THERAPEUTICS, LTD.
EOM PHARMACEUTICAL HOLDINGS, INC. ANNOUNCES NAME CHANGE FROM IMMUNOCELLULAR THERAPEUTICS, LTD.
Company to continue trading on the OTC Markets under the ticker symbol "IMUC" while pursuing listing on a national exchange
MONTVALE, N.J., Nov. 10, 2022 /PRNewswire/ -- EOM Pharmaceutical Holdings, Inc. ("EOM"), a clinical-stage pharmaceutical company, today announced its name change from ImmunoCellular Therapeutics Ltd., to EOM Pharmaceutical Holdings, Inc. EOM's Common Stock will continue to be quoted on the OTC Markets under the ticker symbol "IMUC" while the company completes the process of changing the principal listing of its common stock to a national exchange. No action is required to be taken by company stockholders with respect to the name change.
The company name change follows the merger of EOM Pharmaceuticals, Inc. and ImmunoCellular Therapeutics Ltd. on December 1, 2021, in which the shareholders of EOM Pharmaceuticals became the majority shareholders of the combined company. The merger created a public company that will focus on advancing immunomodulatory and retinal disease investigational drug agents to address a range of inflammatory, viral, retinal, and other diseases.
The senior leadership team at EOM Pharmaceutical Holdings, Inc. includes Chief Executive Officer Irach Taraporewala, Ph.D.; EOM Founder, Board Chairman, and Chief Operating Officer Eli Goldberger; EOM Co-founder, Chief Scientific Officer and Medical Director Shalom Z. Hirschman, M.D; and Wayne I. Danson, Chief Financial Officer and Secretary.
EOM Pharmaceutical Holdings, Inc. is a clinical-stage company focused on developing drugs with the potential to transform therapeutic paradigms and improve quality of life for patients suffering from debilitating and sometimes deadly diseases, including infectious diseases such as COVID-19; autoimmune diseases, including rheumatoid arthritis; cachexia associated with AIDS and cancer; and retinal diseases. For more information about EOM Pharmaceutical Holdings, Inc., please visit .
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Those forward-looking statements include, without limitation, the benefits of the merger, future management and the board of directors of the combined company, statements regarding the ownership in the combined company of the former EOM securityholders and securityholders of ImmunoCellular following the merger, and EOM's respective businesses, future operations, advancement of its product candidates and product pipeline, clinical development of EOM's product candidates, including expectations regarding timing of initiation and results of clinical trials of the company, cash resources of the company, the ability of EOM to remain listed on the OTC Pink Market. In some cases, you can identify these statements by forward-looking words such as "may," "will," "continue," "anticipate," "intend," "could," "project," "expect" or the negative or plural of these words or similar expressions, and other similar terms. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, EOM's ability to develop and commercialize its product candidates; EOM's ability to obtain and maintain regulatory approval of product candidates; EOM's ability to operate in a competitive industry and compete successfully against competitors that have greater resources; EOM's reliance on third parties; EOM's ability to obtain and adequately protect intellectual property rights for product candidates; and the effects of COVID-19 on clinical programs and EOM's business operations. Any forward-looking statements in this press release speak only as of the date of this press release. EOM assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
Contacts:
For EOM Pharmaceuticals Holdings, Inc:
INVESTOR CONTACT: Jane Green
[email protected]
t: 415.652.4819
MEDIA CONTACT: Peter Collins
TogoRun
[email protected]
t. 908.499.1200
SOURCE EOM Pharmaceutical Holdings, Inc.
Company to continue trading on the OTC Markets under the ticker symbol "IMUC" while pursuing listing on a national exchange
公司将继续在场外交易市场交易,股票代码为“IMUC”,同时寻求在国家交易所上市
MONTVALE, N.J., Nov. 10, 2022 /PRNewswire/ -- EOM Pharmaceutical Holdings, Inc. ("EOM"), a clinical-stage pharmaceutical company, today announced its name change from ImmunoCellular Therapeutics Ltd., to EOM Pharmaceutical Holdings, Inc. EOM's Common Stock will continue to be quoted on the OTC Markets under the ticker symbol "IMUC" while the company completes the process of changing the principal listing of its common stock to a national exchange. No action is required to be taken by company stockholders with respect to the name change.
新泽西州蒙特维尔,2022年11月10日/PRNewswire/--临床阶段的制药公司EOM制药控股公司(“EOM”)今天宣布,其名称从免疫细胞治疗有限公司更名为EOM制药控股公司。EOM的普通股将继续在场外交易市场上市,股票代码为“IMUC”,同时该公司完成将其普通股的主要上市改为全国性交易所的过程。公司股东不需要对更名采取任何行动。
The company name change follows the merger of EOM Pharmaceuticals, Inc. and ImmunoCellular Therapeutics Ltd. on December 1, 2021, in which the shareholders of EOM Pharmaceuticals became the majority shareholders of the combined company. The merger created a public company that will focus on advancing immunomodulatory and retinal disease investigational drug agents to address a range of inflammatory, viral, retinal, and other diseases.
在公司更名之前,EOM制药公司和免疫细胞治疗有限公司于2021年12月1日合并,EOM制药公司的股东成为合并后公司的大股东。合并创建了一家上市公司,专注于推进免疫调节和视网膜疾病研究药物,以解决一系列炎症、病毒、视网膜和其他疾病。
The senior leadership team at EOM Pharmaceutical Holdings, Inc. includes Chief Executive Officer Irach Taraporewala, Ph.D.; EOM Founder, Board Chairman, and Chief Operating Officer Eli Goldberger; EOM Co-founder, Chief Scientific Officer and Medical Director Shalom Z. Hirschman, M.D; and Wayne I. Danson, Chief Financial Officer and Secretary.
EOM制药控股公司的高级领导团队包括首席执行官Irach Taraporewala博士;EOM创始人、董事会主席兼首席运营官Eli Goldberger;EOM联合创始人, 首席科学官兼医疗董事首席科学官兼医学博士沙洛姆·Z·赫希曼和首席财务官兼秘书韦恩·I·丹森.
EOM Pharmaceutical Holdings, Inc. is a clinical-stage company focused on developing drugs with the potential to transform therapeutic paradigms and improve quality of life for patients suffering from debilitating and sometimes deadly diseases, including infectious diseases such as COVID-19; autoimmune diseases, including rheumatoid arthritis; cachexia associated with AIDS and cancer; and retinal diseases. For more information about EOM Pharmaceutical Holdings, Inc., please visit .
Eom制药控股公司是一家临床阶段的公司,专注于开发有可能改变治疗模式并提高患者生活质量的药物,这些疾病包括传染性疾病,如新冠肺炎;自身免疫性疾病,包括类风湿性关节炎;与艾滋病和癌症相关的恶病质;以及视网膜疾病。欲了解有关EOM制药控股公司的更多信息,请访问网站。
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Those forward-looking statements include, without limitation, the benefits of the merger, future management and the board of directors of the combined company, statements regarding the ownership in the combined company of the former EOM securityholders and securityholders of ImmunoCellular following the merger, and EOM's respective businesses, future operations, advancement of its product candidates and product pipeline, clinical development of EOM's product candidates, including expectations regarding timing of initiation and results of clinical trials of the company, cash resources of the company, the ability of EOM to remain listed on the OTC Pink Market. In some cases, you can identify these statements by forward-looking words such as "may," "will," "continue," "anticipate," "intend," "could," "project," "expect" or the negative or plural of these words or similar expressions, and other similar terms. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, EOM's ability to develop and commercialize its product candidates; EOM's ability to obtain and maintain regulatory approval of product candidates; EOM's ability to operate in a competitive industry and compete successfully against competitors that have greater resources; EOM's reliance on third parties; EOM's ability to obtain and adequately protect intellectual property rights for product candidates; and the effects of COVID-19 on clinical programs and EOM's business operations. Any forward-looking statements in this press release speak only as of the date of this press release. EOM assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.
本新闻稿包含符合修订后的1933年证券法第27A节和修订后的1934年证券交易法第21E节的前瞻性陈述。这些前瞻性陈述包括但不限于合并的好处、合并后公司的未来管理层和董事会、有关合并后的前EOM证券持有人和免疫细胞公司的证券持有人在合并后公司的所有权以及EOM各自的业务、未来业务、其候选产品和产品流水线的进展、EOM候选产品的临床开发,包括对公司启动临床试验的时间和结果的预期、公司的现金资源、EOM继续在场外交易市场上市的能力的陈述。在某些情况下,您可以通过“可能”、“将会”、“继续”、“预期”、“打算”、“可能”、“项目”、“预期”或这些词的否定或复数或类似表达以及其他类似术语来识别这些陈述。前瞻性陈述不是对未来业绩的保证,会受到风险和不确定性的影响,这些风险和不确定性可能会导致实际结果和事件与预期的结果和事件大不相同,包括但不限于, 这些因素包括:EOM开发其候选产品并将其商业化的能力;EOM获得并保持对候选产品的监管批准的能力;EOM在竞争激烈的行业中运营并成功地与拥有更多资源的竞争对手竞争的能力;EOM对第三方的依赖;EOM获取并充分保护候选产品知识产权的能力;以及新冠肺炎对临床计划和EOM业务运营的影响。本新闻稿中的任何前瞻性陈述仅限于本新闻稿发布之日。EOM没有义务在本新闻稿发布之日之后更新前瞻性陈述,无论是由于新信息、未来事件还是其他原因。
Contacts:
联系人:
For EOM Pharmaceuticals Holdings, Inc:
对于EOM制药控股公司:
INVESTOR CONTACT: Jane Green
[email protected]
t: 415.652.4819
投资者联系方式:简·格林
[受电子邮件保护]
t: 415.652.4819
MEDIA CONTACT: Peter Collins
TogoRun
[email protected]
t. 908.499.1200
媒体联系人:彼得·柯林斯
TogoRun
[受电子邮件保护]
t. 908.499.1200
SOURCE EOM Pharmaceutical Holdings, Inc.
来源:EOM制药控股公司
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧